Biotech News
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
At Week 16, 69% of participants receiving brepocitinib 45 mg achieved "Clear" or "Almost Clear" skin, with at least a 2-category improvement, compared with 0% receiving placebo Improvements in skin disease activity were evident as early as Week 4, increased over time, and were accompanied by
